results

Natural Alternatives International, Inc. Announces 2026 Q2 and YTD Results

February 13, 2026 16:30 ET  | Source: Natural Alternatives International Inc CARLSBAD, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Natural…

3 weeks ago

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

 US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase…

3 weeks ago

Ocean Tomo Releases 2025 Intangible Asset Market Value Study Results

50-year study of the US market and 20 years of foreign market data informs components of market value.NEW YORK, Feb.…

3 weeks ago

Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results

Oslo, Norway, 12th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and…

3 weeks ago

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public…

3 weeks ago

Cellebrite Announces Record Fourth-Quarter and Full-Year 2025 Results

Total ARR grew 21% to $480.8 million; Revenue grew 18% to $128.8 million Net income of $21.3 million supports non-GAAP net…

3 weeks ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

February 11, 2026 06:00 ET  | Source: Upstream Bio – Verekitug provided statistically significant and clinically meaningful reductions in annualized…

3 weeks ago

Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran

BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed…

3 weeks ago

SEMI Reports 2025 Annual Worldwide Silicon Wafer Shipments and Revenue Results

Shipments Increase in 2025 Amid Strong AI-driven Demand, While Revenue SoftensMILPITAS, Calif., Feb. 10, 2026 /PRNewswire/ -- Worldwide silicon wafer…

3 weeks ago

MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer’s Disease

TAINAN, Feb. 10, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive…

3 weeks ago